A pragmatic, randomized, controlled study evaluating the impact of access to smoking cessation pharmacotherapy coverage on the proportion of successful quitters in a Canadian population of smokers motivated to quit (ACCESSATION)

BMC Public Health

Volumn 14, Issue 1, 2014, Pages

  Selby, Peter ^a,b,c   Brosky, Gerald ^d   Oh, Paul ^e   Raymond, Vincent ^f   Arteaga, Carmen ^f   Ranger, Suzanne ^f  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ONTARIO TOBACCO RESEARCH UNIT   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e TORONTO REHABILITATION INSTITUTE   (Canada)

^f PFIZER INC   (United States)

Author keywords

Bupropion; Clinical trial; Medications; Nicotine; Pharmacotherapy coverage; Policy; Pragmatic; Reimbursement; Smoking cessation; Varenicline

Indexed keywords

AMFEBUTAMONE; BENZAZEPINE DERIVATIVE; NICOTINE; NICOTINE GUM; NICOTINIC AGENT; QUINOXALINE DERIVATIVE; VARENICLINE;

CANADA; CONTROLLED STUDY; ECONOMICS; FEMALE; HEALTH CARE DELIVERY; HEALTH INSURANCE; HUMAN; MALE; MIDDLE AGED; MOTIVATION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SMOKING; SMOKING CESSATION; STATISTICS AND NUMERICAL DATA; TOBACCO USE DISORDER; TREATMENT OUTCOME;

BENZAZEPINES; BUPROPION; CANADA; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE, HEALTH; MALE; MIDDLE AGED; MOTIVATION; NICOTINE; NICOTINIC AGONISTS; QUINOXALINES; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 84901022285     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-14-433     Document Type: Article

References (28)

1. World Health Organization, WHO REPORT on the Global Tobacco Epidemic, 2008. The MPOWER package The MPOWER package [ http://www.who.int/tobacco/mpower/ mpower-report-full-2008.pdf ]
2. Nicotine replacement therapy for smoking cessation. Stead LF, Perera R, Bullen C, Mant D, Lancaster T, Cochrane Database Syst Rev 2008 1 CD000146
3. Antidepressants for smoking cessation. Hughes JR, Stead LF, Lancaster T, Cochrane Database Syst Rev 2007 1 CD000031
4. Nicotine receptor partial agonists for smoking cessation. Cahill K, Stead LF, Lancaster T, Cochrane Database Syst Rev 2012 4 CD006103
5. Tran K, Asakawa K, Cimon K, Moulton K, Kaunelis D, Pipe A, Selby P, Pharmacologic-based strategies for Smoking Cessation: Clinical and Cost-effectiveness Analyses [ http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC3442619/ ]
6. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. Eisenberg MJ, Filion KB, Yavin D, Bélisle P, Mottillo S, Joseph L, Gervais A, O'Loughlin J, Paradis G, Rinfret S, Pilote L, CMAJ 2008 179 2 135 144 10.1503/cmaj.070256 18625984 (Pubitemid 352020119)
7. Treatment of tobacco dependence: integrating recent progress into practice. Le Foll B, George TP, CMAJ 2007 177 11 1373 1380 10.1503/cmaj.070627 18025429 (Pubitemid 350207193)
8. Governments, pay for smoking cessation. Penz ED, Manns BJ, Hébert PC, Stanbrook MB, CMAJ 2010 182 18 810 10.1503/cmaj.101140 20805202
9. Healthcare financing systems for increasing the use of tobacco dependence treatment. Reda AA, Kotz D, Evers SM, van Schayck CP, Cochrane Database Syst Rev 2012 6 CD004305
10. How generalisable to community samples are clinical trial results for treatment of nicotine dependence: a comparison of common eligibility criteria with respondents of a large representative general population survey. Le Strat Y, Rehm J, Le Foll B, Tob Control 2011 20 5 338 343 10.1136/tc.2010.038703 21212379
11. How pragmatic or explanatory is the randomized, controlled trial? The application and enhancement of the PRECIS tool to the evaluation of a smoking cessation trial. Selby P, Brosky G, Oh P, Raymond V, Ranger S, BMC Med Res Methodol 2012 12 101 10.1186/1471-2288-12-101 22824225
12. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, Tunis S, Bergel E, Harvey I, Magid DJ, Chalkidou K, CMAJ 2009 180 10 47 E57 10.1503/cmaj.090523 19372436
13. Nicotine addiction and its assessment. Fagerstrom KO, Heatherton TF, Kozlowski LT, Ear Nose Throat J 1990 69 11 763 765 2276350
14. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO, Br J Addict 1991 86 9 1119 1127 10.1111/j.1360-0443. 1991.tb01879.x 1932883
15. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Posner K, Oquendo MA, Gould M, Stanley B, Davies M, A J Psychiatry 2007 164 7 1035 1043 10.1176/appi.ajp.164.7.1035 (Pubitemid 47121392)
16. Fiore FC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline Rockville, MD: U.S. Department of Health and Human Services Public Health Service 2008
17. Measures of abstinence in clinical trials: issues and recommendations. Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE, Nicotine Tob Res 2003 5 1 13 25 10.1093/ntr/5.1.13 12745503 (Pubitemid 36285465)
18. Assessment of validity of self-reported smoking status. Wong SL, Shields M, Leatherdale S, Malaison E, Hammond D, Health Rep 2012 23 1 47 53 22590805
19. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR, JAMA 2006 296 1 47 55 10.1001/jama.296.1.47 16820546
20. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR, JAMA 2006 296 1 56 63 10.1001/jama.296.1.56 16820547
21. Healthcare financing systems for increasing the use of tobacco dependence treatment. Kaper J, Wagena EJ, Severens JL, Van Schayck CP, Cochrane Database Syst Rev 2005 1 CD004305
22. A randomized controlled trial to assess the effects of reimbursing the costs of smoking cessation therapy on sustained abstinence. Kaper J, Wagena EJ, Willemsen MC, van Schayck CP, Addiction 2006 101 11 1656 1661 10.1111/j.1360-0443.2006.01578.x 17034446 (Pubitemid 44527198)
23. Shape of the relapse curve and long-term abstinence among untreated smokers. Hughes JR, Keely J, Naud S, Addiction 2004 99 1 29 38 10.1111/j.1360-0443.2004.00540.x 14678060 (Pubitemid 38142221)
24. Reimbursement for smoking cessation treatment may double the abstinence rate: results of a randomized trial. Kaper J, Wagena EJ, Willemsen MC, van Schayck CP, Addiction 2005 100 7 1012 1020 10.1111/j.1360-0443.2005.01097.x 15955017 (Pubitemid 40897296)
25. The clinical significance of small effects of smoking cessation treatments. West R, Addiction 2007 102 4 506 509 17362283 (Pubitemid 46398840)
26. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D, BMJ 2008 337 2390 10.1136/bmj.a2390 19001484
27. Variations in treatment benefits influence smoking cessation: results of a randomised controlled trial. Schauffler HH, McMenamin S, Olson K, Boyce-Smith G, Rideout JA, Kamil J, Tob Control 2001 10 2 175 180 10.1136/tc.10.2.175 11387540 (Pubitemid 33720583)
28. New methods for tobacco dependence treatment research. Baker TB, Mermelstein R, Collins LM, Piper ME, Jorenby DE, Smith SS, Christiansen BA, Schlam TR, Cook JW, Fiore MC, Ann Behav Med 2011 41 2 192 207 10.1007/s12160-010-9252-y 21128037